Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of disitamab vedotin in HER2-altered advanced melanoma
CTR20212908Phase 2Active
- Sponsor
- RemeGen
- Start
- May 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in melanoma, sponsored by RemeGen. Started May 2022; status: active.
02
Drugs
disitamab vedotin
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20212908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212908.